Deepika Vasudevan1, Hideyuki Takeuchi1, Sumreet Singh Johar1, Elaine Majerus2, Robert S Haltiwanger3. 1. Department of Biochemistry and Cell Biology, 450 Life Sciences Building, Stony Brook University, Stony Brook, NY 11794-5215, USA. 2. Department of Internal Medicine, Division of Hematology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA. 3. Department of Biochemistry and Cell Biology, 450 Life Sciences Building, Stony Brook University, Stony Brook, NY 11794-5215, USA. Electronic address: robert.haltiwanger@stonybrook.edu.
Abstract
BACKGROUND: O-fucose is added to cysteine-rich domains called thrombospondin type 1 repeats (TSRs) by protein O-fucosyltransferase 2 (POFUT2) and is elongated with glucose by β3-glucosyltransferase (B3GLCT). Mutations in B3GLCT result in Peters plus syndrome (PPS), an autosomal recessive disorder characterized by eye and other developmental defects. Although 49 putative targets are known, the function of the disaccharide and its role in PPS remain unexplored. RESULTS: Here we show that while POFUT2 is required for secretion of all targets tested, B3GLCT only affects the secretion of a subset, consistent with the observation that B3GLCT mutant phenotypes in PPS patients are less severe than embryonic lethal phenotypes of Pofut2-null mice. O-glycosylation occurs cotranslationally, as TSRs fold. Mass spectral analysis reveals that TSRs from mature, secreted protein are stoichiometrically modified with the disaccharide, whereas TSRs from protein still folding in the ER are partially modified, suggesting that O-glycosylation marks folded TSRs and promotes ER exit. In vitro unfolding assays demonstrate that fucose and glucose stabilize folded TSRs in an additive manner. In vitro refolding assays under redox conditions showed that POFUT2 recognizes, glycosylates, and stabilizes the folded form of TSRs, resulting in a net acceleration of folding. CONCLUSIONS: While known ER quality-control machinery rely on identifying and tagging unfolded proteins, we find that POFUT2 and B3GLCT mediate a noncanonical ER quality-control mechanism that recognizes folded TSRs and stabilizes them by glycosylation. Our findings provide a molecular basis for the defects observed in PPS and potential targets that contribute to the pathology.
BACKGROUND:O-fucose is added to cysteine-rich domains called thrombospondin type 1 repeats (TSRs) by protein O-fucosyltransferase 2 (POFUT2) and is elongated with glucose by β3-glucosyltransferase (B3GLCT). Mutations in B3GLCT result in Peters plus syndrome (PPS), an autosomal recessive disorder characterized by eye and other developmental defects. Although 49 putative targets are known, the function of the disaccharide and its role in PPS remain unexplored. RESULTS: Here we show that while POFUT2 is required for secretion of all targets tested, B3GLCT only affects the secretion of a subset, consistent with the observation that B3GLCT mutant phenotypes in PPSpatients are less severe than embryonic lethal phenotypes of Pofut2-null mice. O-glycosylation occurs cotranslationally, as TSRs fold. Mass spectral analysis reveals that TSRs from mature, secreted protein are stoichiometrically modified with the disaccharide, whereas TSRs from protein still folding in the ER are partially modified, suggesting that O-glycosylation marks folded TSRs and promotes ER exit. In vitro unfolding assays demonstrate that fucose and glucose stabilize folded TSRs in an additive manner. In vitro refolding assays under redox conditions showed that POFUT2 recognizes, glycosylates, and stabilizes the folded form of TSRs, resulting in a net acceleration of folding. CONCLUSIONS: While known ER quality-control machinery rely on identifying and tagging unfolded proteins, we find that POFUT2 and B3GLCT mediate a noncanonical ER quality-control mechanism that recognizes folded TSRs and stabilizes them by glycosylation. Our findings provide a molecular basis for the defects observed in PPS and potential targets that contribute to the pathology.
Authors: E Weh; L M Reis; R C Tyler; D Bick; W J Rhead; S Wallace; T L McGregor; S K Dills; M-C Chao; J C Murray; E V Semina Journal: Clin Genet Date: 2013-09-17 Impact factor: 4.438
Authors: J Hofsteenge; K G Huwiler; B Macek; D Hess; J Lawler; D F Mosher; J Peter-Katalinic Journal: J Biol Chem Date: 2000-11-06 Impact factor: 5.157
Authors: G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai Journal: Nature Date: 2001-10-04 Impact factor: 49.962
Authors: Anne Gonzalez de Peredo; Dominique Klein; Boris Macek; Daniel Hess; Jasna Peter-Katalinic; Jan Hofsteenge Journal: Mol Cell Proteomics Date: 2002-01 Impact factor: 5.911
Authors: Sachin Khurana; Michael J Coffey; Alan John; Alessandro D Uboldi; My-Hang Huynh; Rebecca J Stewart; Vern B Carruthers; Christopher J Tonkin; Ethan D Goddard-Borger; Nichollas E Scott Journal: J Biol Chem Date: 2018-12-04 Impact factor: 5.157
Authors: Carolin M Hoppe; Andreia Albuquerque-Wendt; Giulia Bandini; Deborah R Leon; Aleksandra Shcherbakova; Falk F R Buettner; Luis Izquierdo; Catherine E Costello; Hans Bakker; Françoise H Routier Journal: Glycobiology Date: 2018-05-01 Impact factor: 4.313
Authors: D Marques-da-Silva; R Francisco; D Webster; V Dos Reis Ferreira; J Jaeken; T Pulinilkunnil Journal: J Inherit Metab Dis Date: 2017-07-19 Impact factor: 4.982
Authors: Ao Zhang; Steven J Berardinelli; Christina Leonhard-Melief; Deepika Vasudevan; Ta-Wei Liu; Andrew Taibi; Sharee Giannone; Suneel S Apte; Bernadette C Holdener; Robert S Haltiwanger Journal: J Biol Chem Date: 2020-09-10 Impact factor: 5.157